StonvexLoading…
StonvexStonvexStonvexCore line items from NGVT's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $258.00M | $1.17B | $912.50M | $649.10M |
Operating Income | $30.20M | $418.70M | $-36.70M | $-115.90M |
Net Income | $59.80M | $-167.10M | $-82.50M | $-146.50M |
EPS (Diluted) | $1.66 | $-4.61 | $-2.27 | $-3.46 |
Total Assets | $1.65B | $1.65B | $1.83B | $1.88B |
Total Liabilities | $1.61B | $1.62B | $1.70B | $1.76B |
Cash & Equivalents | $95.40M | $78.10M | $83.40M | $76.90M |
Free Cash Flow OCF − CapEx | $-12.30M | $273.50M | $200.00M | $82.20M |
Shares Outstanding | 34.89M | 35.49M | 36.05M | 36.47M |